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Glucagon-like peptide 2 (GLP-2) analogues represent the ﬁrst To address effects of a novel long-acting GLP-2 analogue,
medical therapy, which has truly proven to reduce the requirement
for parenteral support in patients with intestinal failure due to short
bowel syndrome [1]. During GLP-2 treatment, patients with short
bowel syndrome show improved intestinal absorption in conjunction
with increased villus height, crypt depth and mesenteric blood ﬂow.
Despite the well-documented and striking ability of GLP-2 analogues
tomodulate intestinal physiology, and plethora of previous clinical trials
recapitulating the positive effects on intestinal function and parenteral
support requirements, very few clinical or experimental studies have
addressed consequences of GLP-2 therapy on liver function in short
bowel syndrome thus far. This appears rather surprising at a time in
which the signiﬁcance of the gut-liver axis is drawing increasingly at-
tention among research laboratories worldwide in a search of novel
therapies for a variety of hepatobiliary diseases.
Oneof themost signiﬁcant complicationsof short bowel syndrome is
a unique type of liver injury referred to as intestinal failure associated
liver disease (IFALD) without any efﬁcient medical therapy currently
available. Liver histology typically features inﬂammation and cholestasis
with variable progression of ﬁbrosis and steatosis, associated with in-
creasedbiochemicalmarkers of cholestasis and liver injury,while gener-
ally accepted diagnostic criteria for IFALD are still missing [2]. Around
25–60%of patientswith intestinal failure demonstrate advanced liver ﬁ-
brosis at the time of assessment for intestinal transplantation [3,4].
IFALD results from combined consequences of compromised intestinal
function and parenteral nutrition. Based on a mouse model recapitulat-
ing the pathophysiology in humans, biliary secretion of bile acids, sterols
and bilirubin is impaired due to suppression of their upstream nuclear
receptors, farnesoid X receptor (FXR) and liver X receptor, and respec-
tive canalicular bile transporters by macrophages activated synergisti-
cally by bowel derived bacterial pathogens and plant sterols, present in
all parenteral vegetable oil lipid preparations [5,6]. Surgical resection
and inﬂammation of the ileum further interferes with FXR signaling by
interrupting the enterohepatic circulation of bile acids and reducing
ﬁbroblast growth factor 19 secretion, which upregulates bile acid
synthesis and exacerbates primary bile acid overload induced injury to
hepatocytes with malfunctioning canalicular bile secretion [7,8].DOI of original article: https://doi.org/10.1016/j.ebiom.2019.07.016.
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drome, Naimi et al. studied markers of liver function, bacterial translo-
cation and macrophage activation in their randomized, double blind,
dose-ﬁnding, cross-over phase two trial including 16 patients with
normal or near normal biochemistry [9]. After three weeks treatment
period with 10 mg dose, indocyanine green clearance increased and
plasmabilirubin loweredminimally, while plasma alkaline phosphatase
decreased in the 1 mg dose group, suggesting a beneﬁcial effect of
glepaglutide on hepatic excretory function. Unexpectedly, plasma solu-
ble CD163, a marker for macrophage activation, increased signiﬁcantly
and another surrogate used for macrophage activation, soluble man-
nose receptor, tended to also increase (P = .068) in the 10 mg dose
group. The magnitude of the soluble mannose receptor increase was
comparable with changes following 0·1 mg dose (0·03 mg/mL; P =
0·115). No signiﬁcant changes occurred in the low base line plasma
concentration of lipopolysaccharide binding protein, a surrogate for
bacterial translocation, and in liver stiffness, which, if anything, tended
to increase in the 10 mg dose group.
Although this study may have produced more questions than
answers, authors should be congratulated for addressing hepatobiliary
effects and the underlying mechanisms of a GLP-2 analogue in a ran-
domized study design for the ﬁrst time. While hepatic excretory func-
tion seemed to improve during glepaglutide treatment, enhanced liver
macrophage activation would be an unwanted harmful effect, which
clearly requires careful reassessment in future clinical trials with larger
patient cohorts and longer treatment periods. In this respect, it would
be valuable to measure serum plant sterol concentrations, while focus-
ing on parenteral nutrition-dependent patients and individuals with
established IFALD, who aremore likely to exhibit increased livermacro-
phage activation and bacterial translocation alongwith raised biochem-
ical markers of cholestasis, including bile acids, already at baseline. Only
then, one could really test, whether intestinotrophic properties of
glepaglutide would reduce bacterial translocation by improving intesti-
nal epithelial barrier function resulting in decreasedmacrophage activa-
tion and improvement in cholestasis, or unexpectedly, conﬁrm the
increased macrophage activation as suggested by the current study. Of
note, the three patients with the highest and above normal soluble
CD163 concentration at base linewere heavily dependent on parenteral
support, had a very short remaining intestine ≤50 cm and showed in-
creased biochemical markers of cholestasis, hinting that intestinal com-
promise, parenteral nutrition, macrophage activation and cholestasisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
12 M.P. Pakarinen / EBioMedicine 46 (2019) 11–12were linked in these patients. When interpreting the results of Naimi
et al., one should also note that indocyanine green clearance may not
reliably reﬂect canalicular bile acid secretion as they seem to utilize
different canalicular transporters [10]. Obviously, detailed mechanistic
understanding how GLP-2 analogues modulate the gut-liver axis and
liver function in short bowel syndrome requires translational basic
research. It would be desirable that these models combine parenteral
nutrition with extensive bowel resection involving distal small bowel
and colon mimicking the underlying pathophysiology frequently
encountered in patients.
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